法舒地尔联合尿激酶治疗高凝状态肾病综合征

Treatment of Fasudil Combined with Urokinase for Nephritic Syndrome Patients with Hypercoagulable State

目的:探讨法舒地尔联合尿激酶治疗高凝状态肾病综合征的临床疗效。方法:2013年1月至2015年1月期间,本院诊治的60例高凝状态肾病综合征患者,根据随机数字法,将其分为对照组(常规治疗)和观察组(法舒地尔联合尿激酶),每组各30例,对比两组治疗后2周、4周、8周,患者24 h尿蛋白定量、血浆白蛋白、总胆固醇,以及凝血酶原时间(PT)、部分凝血酶原时间(APTT)、纤维蛋白原(FDP)变化情况,并观察治疗期间的不良反应。结果:与治疗前相比,两组治疗后2周、4周、8周时24 h尿蛋白定量、总胆固醇、FDP明显降低,血浆白蛋白明显升高,PT及APTT明显延长(P<0.05);两组治疗后相比,上述指标差异均有统计学意义(P<0.05)。治疗期间未出现明显的不良反应。结论:法舒地尔联合尿激酶能够明显改善肾病综合征患者的高凝状态,降低蛋白尿水平。

Objective To observe the clinical efficacy of fasudil combined with urokinase in treating nephritic syndrome with hypercoagulable state. Methods From January 2013 to January 2015,60 patients with nephritic syndrome complicating hypereoagulable state in our hospital were randomly divided into control group and observation group （fasudil combined with urokinase） according to the randomized number method. The changes of 24 h urine protein,plasma albumin,total cholesterol,the prothrombin time（PT） ,partial thromboplastin time（APTF） and fibrinogen（FDP） in two groups were analyzed and compared at 2,4 and 8 weeks after treatment. The adverse reactions were observed following the treatment. Results Com- pared with control group, the 24 h urine protein and total cholesterol were significantly decreased, and the plasma albumin was obviously increased in the observation group at 2,4 and 8 weeks （ P 〈 0.05 ）. Compared with before treatment within groups, the PT and APTF times were significantly prolonged ,and the FDP was obviously reduced at 2,4 and 8 weeks after treatment（ P 〈 0.05 ）. No obvious adverse reactions was observed during the treatment period. Conclusion The treatment of fasudil combined with urokinase could obviously improve the high coagulation state and reduce the proteinuria levels of pa- tients with nephritic syndrome.